RxDoctor Payments Data

Kayla Gatto

Psychiatric/Mental Health · Jermyn, PANPI 1124690219

Payments from drug & device makers

$1,619in general payments, 2019–2025

Across 79 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Braeburn Inc.$194
  • AstraZeneca$168
  • AbbVie$159
  • Indivior Inc.$129
  • Gilead$123
  • Johnson & Johnson$113
  • plus $733 from 15 others

What the payments were for

  • Food & beverage$1,619100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,619 in reported general payments places this provider in the 70th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,396
Medicare patients
33
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide14$12,515
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl88$6,134
Fluoxetine Hcl11$686
Losartan Potassium25$578
Atorvastatin Calcium34$389
Albuterol Sulfate HfaAlbuterol Sulfate12$343
Quetiapine Fumarate42$292
Lisinopril33$271
Gabapentin23$254
Metoprolol Succinate17$211
Amlodipine Besylate20$193
Cephalexin15$190
Azelastine Hcl19$187
Hydroxyzine Hcl23$177
Omeprazole29$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$23$12,51514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Jermyn

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →